Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of endometrial cancer
3.2.1.2 Advancements in diagnostic techniques
3.2.1.3 Growing awareness and focus on women's health
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatment
3.2.2.2 Side effects associated with the treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Cancer Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Endometrial carcinoma
5.3 Uterine sarcoma
Chapter 6 Market Estimates and Forecast, By Treatment, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Surgery
6.3 Chemotherapy
6.4 Radiation therapy
6.5 Hormone therapy
6.6 Targeted therapy
6.7 Immunotherapy
Chapter 7 Market Estimates and Forecast, By Stage, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Stage I
7.3 Stage II
7.4 Stage III
7.5 Stage IV
Chapter 8 Market Estimates and Forecast, By Treatment Provider, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospitals
8.3 Cancer centers
8.4 Ambulatory surgical centers
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Medication manufacturers
10.1.1 Alpine Life Sciences Private Limited
10.1.2 AstraZeneca PLC
10.1.3 Eisai Co., Ltd.
10.1.4 GSK plc
10.1.5 Merck & Co., Inc.
10.1.6 Novartis AG
10.1.7 Pfizer Inc.
10.1.8 Varian Medical Systems, Inc. (Siemens Healthineers AG)
10.1.9 Sun Pharmaceutical Industries Limited
10.1.10 Teva Pharmaceutical Industries Ltd.
10.2 Service providers
10.2.1 Brigham and Women's Hospital
10.2.2 Mayo Foundation for Medical Education and Research (MFMER)
10.2.3 The University of Texas MD Anderson Cancer Center
10.2.4 Institut Gustave Roussy
10.2.5 National Cancer Center Research Institute
